Vociprotafib

Cat. No.: HY-141523

CAS No.: 2172652-48-9

Molecular Formula: $C_{20}H_{27}ClN_6O_2S$

Molecular Weight: 450.99

Target: Phosphatase; SHP2

Pathway: Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (110.87 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.2173 mL	11.0867 mL	22.1734 mL
	5 mM	0.4435 mL	2.2173 mL	4.4347 mL
	10 mM	0.2217 mL	1.1087 mL	2.2173 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.54 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.54 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.54 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Vociprotafib (RMC-4630) is a SHP2 inhibitor, a phosphatase whose inhibition blocks activation of the RAS-RAF-MEK-ERK signaling pathway. Vociprotafib has antitumor activity[1][2].

IC_{50} & Target

SHP2[1]

REFERENCES

[1]. Smith J A, et al. SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway. Cancer Research, 2020, 80(16_Supplement): 1943-1943.

[2]. WO2018013597

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA